{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epivir+%283TC%29&page=13", "query": { "intervention": "Epivir (3TC)", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 312, "total_pages": 32, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epivir+%283TC%29&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epivir+%283TC%29&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T11:32:12.808Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03441984", "title": "To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Treatment A", "type": "DRUG" }, { "name": "Treatment B", "type": "DRUG" }, { "name": "Treatment C", "type": "DRUG" }, { "name": "Treatment D", "type": "DRUG" }, { "name": "Treatment E", "type": "DRUG" }, { "name": "Treatment F", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 36, "start_date": "2018-02-26", "completion_date": "2018-04-28", "has_results": true, "last_update_posted_date": "2019-12-09", "last_synced_at": "2026-10-14T11:32:12.808Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03441984" }, { "nct_id": "NCT03016533", "title": "Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Dolutegravir film-coated tablets", "type": "DRUG" }, { "name": "Dolutegravir film-coated dispersible tablets", "type": "DRUG" }, { "name": "ABC/DTG/3TC immediate release tablets", "type": "DRUG" }, { "name": "ABC/DTG/3TC film-coated dispersible tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "25 Years", "sex": "ALL", "summary": "Up to 25 Years" }, "enrollment_count": 100, "start_date": "2017-06-06", "completion_date": "2024-12-24", "has_results": true, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-14T11:32:12.808Z", "location_count": 3, "location_summary": "Los Angeles, California • Fort Lauderdale, Florida • Memphis, Tennessee", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03016533" }, { "nct_id": "NCT00002108", "title": "3TC (Lamivudine; GR109714X) Open-Label Program", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Lamivudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glaxo Wellcome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-14T11:32:12.808Z", "location_count": 1, "location_summary": "Morristown, New Jersey", "locations": [ { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002108" }, { "nct_id": "NCT00005106", "title": "A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Lamivudine/Zidovudine", "type": "DRUG" }, { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glaxo Wellcome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "1999-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-14T11:32:12.808Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Longbeach, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Longbeach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005106" }, { "nct_id": "NCT00002451", "title": "Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-14T11:32:12.808Z", "location_count": 3, "location_summary": "Miami, Florida • Albany, New York • Stony Brook, New York", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Albany", "state": "New York" }, { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002451" }, { "nct_id": "NCT00350272", "title": "Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Elvucitabine", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Tenofovir", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 76, "start_date": "2006-05", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2023-08-30", "last_synced_at": "2026-10-14T11:32:12.808Z", "location_count": 25, "location_summary": "Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 17 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Clearwater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00350272" }, { "nct_id": "NCT00004999", "title": "Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Lamivudine/Zidovudine", "type": "DRUG" }, { "name": "Capravirine", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agouron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 350, "start_date": "1999-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-14T11:32:12.808Z", "location_count": 46, "location_summary": "Tucson, Arizona • Los Angeles, California • Oakland, California + 39 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004999" }, { "nct_id": "NCT00000896", "title": "A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Lamivudine/Zidovudine", "type": "DRUG" }, { "name": "Hepatitis A Vaccine (Inactivated)", "type": "BIOLOGICAL" }, { "name": "Interleukin-12", "type": "DRUG" }, { "name": "Nevirapine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Sargramostim", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": null, "completion_date": "2000-10", "has_results": false, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-10-14T11:32:12.808Z", "location_count": 3, "location_summary": "San Diego, California • Aurora, Colorado • Indianapolis, Indiana", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000896" }, { "nct_id": "NCT04283656", "title": "Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Transgender Health", "Gender Dysphoria", "Transgender Women", "Human Immunodeficiency Virus" ], "interventions": [ { "name": "Doravirine/Lamivudine/Tenofovir", "type": "DRUG" }, { "name": "Spironolactone 100mg", "type": "DRUG" }, { "name": "Estradiol 2mg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 8, "start_date": "2022-01-04", "completion_date": "2022-12-30", "has_results": true, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-10-14T11:32:12.808Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04283656" }, { "nct_id": "NCT01363011", "title": "Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "E/C/F/TDF", "type": "DRUG" }, { "name": "COBI", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "NRTI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2011-05", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-05-02", "last_synced_at": "2026-10-14T11:32:12.808Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01363011" } ] }